Ronald D'Amico, DO, MSc

Medical Director
ViiV Healthcare

Disclosure: GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee)

Dr. Ronald D’Amico is an Infectious Disease Physician with over twenty years of experience in HIV clinical medicine. He received his Medical Degree from Midwestern University in Chicago and continued his training in Internal Medicine at Loyola University Medical Center. He went on to complete a Fellowship in Infectious Diseases at Rush Medical College in 1997. He has worked as a co-investigator of the AIDS Clinical Trials Group (ACTG) at Beth Israel Medical Center in NYC where he was also an Associate Professor of Clinical Medicine from 1998-2006.

In 2006, Dr. D’Amico earned a master’s degree in Medical Microbiology at the London School of Hygiene and Tropical Medicine where he completed a molecular Virology research thesis exploring co-receptor usage in non-clade B HIV viruses. He received an excellence award from the London School for this research. Dr. D’Amico has led training courses in Kampala, Uganda for physicians and allied health care professionals on various aspects related to the administration of antiretroviral therapies in resource limited settings. He joined Abbott/AbbVie in 2010 as an Associate Medical Director. His responsibilities included the medical oversight of Aluvia (AbbVie’s protease inhibitor marketed for resource limited settings) in African and was a core member on the launch team for ViKera-Pak, AbbVie’s direct acting antiviral medication for HCV infection.

In 2015, Dr D’Amico joined ViiV Healthcare as a Senior Medical Director and was responsible for various medical aspects related to dolutegravir, ViiV’s HIV integrase inhibitor. In the fall of 2016, Dr D’Amico transitioned to Clinical Development where he currently is a Medical Director and a core member on the cabotegravir (CAB) launch team. In this capacity, he has been the medical monitor for several P1 and P3 CAB related clinical studies and leads the global compassionate use program for cabotegravir at ViiV Healthcare.